Explosive growth of uterine leiomyomas and carcinologic ovarian risk in patient with BRCA1-BRCA2 mutation treated by tamoxifen;Croissance explosive de myome utérin et risque carcinologique ovarien sous tamoxifène chez une patiente non ménopausée porteuse d'une mutation BRCA1-BRCA2

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 31, Issue 7, 2002, Pages 677-680

  Doridot, V ^a   This, P ^a   Clough, Krishna B ^a  

^a INSTITUT CURIE   (France)

Author keywords

BRCA1 BRCA2 mutation; Myoma; Ovarian cancer; Premenopausal; Tamoxifen

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CASE REPORT; CLINICAL EXAMINATION; DIAGNOSTIC IMAGING; ECHOGRAPHY; FEMALE; GENE MUTATION; HUMAN; LAPAROTOMY; MYOMECTOMY; ONCOGENE; OVARY CARCINOMA; PREMENOPAUSE; SURGICAL APPROACH; TUMOR GROWTH; UTERUS MYOMA;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOGENS; CARCINOMA; COMBINED MODALITY THERAPY; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; HYSTERECTOMY; LAPAROSCOPY; LEIOMYOMA; MASTECTOMY; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; OVARIAN NEOPLASMS; PREMENOPAUSE; RISK FACTORS; TAMOXIFEN; UTERINE NEOPLASMS;

EID: 0036858797     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Early Breast Cancer Trialists'Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998; 351: 1451-65.
2. Standards, Options et Recommandations (SOR): Hormonothérapie dans les cancers du sein non métastatiques. Bull Cancer 2000; 87: 469-90.
3. Gerhard I, Runnebaum B. Comparison between Tamoxifen and Clomiphen therapy in women with anovulation. Arch Gynecol 1979; 227: 279-88.
4. Ismail SM. Gynaocological effects of tamoxifen. J Clin Pathol 1999; 52: 83-8.
5. Cohen I, Figer A, Tepper R, Shapira J, Altaras MM, Ygael D, Beyth Y. Ovarian overstimulation and cystic formation in premenopausal Tamoxifen exposure: Comparison between Tamoxifen-treated and non treated breast cancer patients. Gynecol Oncol 1999; 72: 202-7.
6. Boudouris O, Ferrand S, Guillet JL, Madelenat P. Paradoxical effects of tamoxifen on the woman's uterus. J Gynecol Obstet Biol Reprod 1989; 18: 372-8.
7. Rullo S, Tagliaferri T, Bandiera F, Fiorelli C, Felici A, Piccioni MG, Framarino dei Malatesta ML. Uterine changes during tamoxifen therapy. Clin Exp Obstet Gynecol 1993; 20: 116-9.
8. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994; 343: 1318-21.
9. Schwartz LB, Rutkowski N, Horan C, Nachtigall LE, Snyder J, Goldstein SR. Use of transvaginal ultrasonography to monitor the effects of tamoxifen on uterine leiomyoma size and ovarian cyst formation. J Ultrasound Med 1998; 17: 699-703.
10. Fisher B, Costantino JP, Wickerman DL. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P1 Study. J Natl Cancer Inst 1998; 90: 1371-88.
11. Bernstein L, Deapen D, Cerhan JR. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999; 91: 1654-62.
12. Barakat RR, Gilewski TA, Almadrones L, Saigo PE, Venkatraman E, Hudis C, Hoskins WJ. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: A prospective study using office endometrial biopsy. J Clin Oncol 2000; 8: 3459-63.
13. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: A review. Obstet Gynecol 2001; 97: 855-66.
14. Cohen I, Azaria R, Bernheim J, Shapira J, Beyth Y. Risk factors of endometrial polyps resected from postmenopausal patients with breast carcinoma treated with tamoxifen. Cancer 2001; 92: 1151-5.
15. Dilts PV, Hopkins MP, Chang AE, Cody RL. Rapid growth of leiomyoma in patients receiving tamoxifen. Am J Obstet Gynecol 1992; 166: 167-8.
16. Le Bouëdec G, De Latour M, Dauplat J. Expansive uterine fibropyomas in eleven women treated with tamoxifen. Presse Med 1995; 24: 1694-6.
17. Lumsden MA, West CP, Baird DT. Tamoxifen prolongs luteal phase in premenopausal women but has no effect on the size of uterine fibroids. Clinical Endocrinol 1989; 31: 335-43.
18. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet 1988: 563.
19. Bocklage T, Lee KR, Belinson JL. Uterine mullerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy. Gynecol Oncol 1992; 44: 104-9.
20. Silva EG, Tornos CS, Follen-Mitchel M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: The effects of tamoxifen. Int J Gynecol Pathol 1994; 13: 248-58.
21. McCluggage WG, Varma M, Weir P, Bharucha H. Uterine leiomyosarcoma in patient receiving tamoxifen therapy. Acta Obstet Gynecol Scand 1996; 76: 593-5.
22. Chew SB, Carmald H, Gillett D. Leiomyosarcoma of the uterus in a woman on adjuvant tamoxifen therapy. The Breast 1996; 5: 429-31.
23. Sasco AJ, Ah-Song R, Gendre I, Zlatoff P, Bobin JY, Hallonet P, et al. Cancer de l'endomètre et tamoxifène. Discussion à partir d'une série de cas. Bull Cancer 1997; 84: 51-60.
24. Sabatini R, Difazio F, Loizzi P. Uterine leiomyosarcoma in a postmenopausal woman treated with tamoxifen: Case report. Eur J Gynaecol Oncol 1999; 20: 327-9.
25. Le Bouedec G, Auvray H, Cure H, de Latour M, Penault-Llorca F, Dauplat J. Uterine sarcoma in patients receiving tamoxifen therapy. Rev Med Interne 2001; 221: 881-5.
26. Altaras MM, Aviram R, Cohen I, Cordoba M, Yarkoni S, Beyth Y, et al. Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas. Gynecol Oncol 1993; 49: 255-8.
27. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the national surgical adjuvant breast and bowel projet (NSAPB) B-14. J Natl Cancer Inst 1994; 86: 527-37.
28. Beer TW, Buchanan R, Buckley CH. Uterine stromal sarcoma following tamoxifen treatment. J Clin Pathol 1995; 18: 596.
29. Pang LC. Endometrial stromal sarcoma with sex cord-like differentiation associated with tamoxifen therapy. Southern Med 1998; 91: 592-4.
30. Gnagy S, Ming EE, Devesa SS, Hartge P, Whittemore AS. Declining ovarian cancer rates in U.S. women in relation to parity and oral contraceptive use. Epidemiol 2000; 11: 102-5.
31. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998; 339: 424-8.
32. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 235-40.
33. Spicer DV, Pike MC, Henderson BE. Ovarian cancer and long-term tamoxifen in premenopausal women. Lancet 1999; 337: 1414.